QuantHealth
AI software simulates clinical trials before patient enrollment to help drug developers assess study design and outcome risks.
Overview
QuantHealth builds an AI platform for simulating clinical trials before patients enroll, aiming to help life sciences teams evaluate trial designs and anticipate risks earlier in development. The company targets pharmaceutical and biotech organizations seeking to improve clinical development decisions. Its key differentiator is the use of AI-driven trial simulation as a pre-enrollment planning tool. QuantHealth raised a $45 million Series B in August 2026, bringing total disclosed funding to $45 million.
Funding History
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
Frequently Asked Questions
- How much funding does AI Funding track for QuantHealth?
- AI Funding tracks $45M for QuantHealth across 1 funding round in this database.
- Who are QuantHealth's investors?
- QuantHealth's investors include Qumra Capital.
- What does QuantHealth do?
- QuantHealth builds an AI platform for simulating clinical trials before patients enroll, aiming to help life sciences teams evaluate trial designs and anticipate risks earlier in development. The company targets pharmaceutical and biotech organizations seeking to improve clinical development decisions. Its key differentiator is the use of AI-driven trial simulation as a pre-enrollment planning tool. QuantHealth raised a $45 million Series B in August 2026, bringing total disclosed funding to $45 million.
- Where is QuantHealth headquartered?
- QuantHealth is headquartered in Tel Aviv, Israel.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.